Optimal treatment of chronic constipation in managed care: Review and roundtable discussion

Journal of Managed Care Pharmacy

Volumn 14, Issue 9 SUPPL. A, 2008, Pages

  Eoff III, James C ^a   Lembo, Anthony J ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; 17 METHYLNALTREXONE BROMIDE; ALVIMOPAN; ANTHRAQUINONE DERIVATIVE; BISACODYL; CALCIUM; DIPHENYLMETHANE DERIVATIVE; DOCUSATE CALCIUM; DOCUSATE SODIUM; EMOLLIENT AGENT; GUANYLATE CYCLASE ACTIVATOR; INTESTINE CONTRACTION STIMULATING AGENT; IRON; ISPAGULA; LACTULOSE; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MACROGOL; MACROGOL 3350; MAGNESIUM HYDROXIDE; METHYLCELLULOSE; MINERAL OIL; PLACEBO; POLYCARBOPHIL CALCIUM; PRUCALOPRIDE; SENNA EXTRACT; SENNOSIDE; TEGASEROD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANGINA PECTORIS; ANUS FISSURE; BLOATING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC CONSTIPATION; CLINICAL TRIAL; COLONOSCOPY; CONSTIPATION; COST OF ILLNESS; DIARRHEA; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; FECES IMPACTION; FECES INCONTINENCE; FEEDBACK SYSTEM; FLATULENCE; HEALTH CARE COST; HEALTH CARE QUALITY; HEART INFARCTION; HEMORRHOID; HUMAN; INTESTINE OBSTRUCTION; MANAGED CARE; MEDICAL TECHNOLOGY; NAUSEA; PATHOPHYSIOLOGY; PATIENT CARE; PREVALENCE; QUALITY OF LIFE; RADIODIAGNOSIS; RECOMMENDED DRUG DOSE; RECTUM PROLAPSE; RELAXATION TRAINING; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VOLVULUS;

AGE FACTORS; AGED; CHRONIC DISEASE; CONSTIPATION; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; QUALITY ASSURANCE, HEALTH CARE; QUALITY OF LIFE; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 57749109928     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99(4):750-59.
2. Pleis JR, Lethbridge-Çejku M. Summary health statistics for U.S. adults: National Health Interview Survey, 2006. National Center for Health Statistics. Vital Health Stat. 2007;10(235):1-153.
3. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001;96(11):3130-37.
4. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599-608.
5. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.
6. Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Cumulative incidence of chronic constipation: a population-based study 1988-2003. Aliment Pharmacol Ther. 2007;26(11-12):1521-28.
7. Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum. 1989;32(1):1-8.
8. Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. Manag Care Interface. 2006;19(12):43-49.
9. Locke GR 3rd, Pemberton JH, Phillips SF. AGA technical review on constipation. American Gastroenterological Association. Gastroenterology. 2000;119(6):1766-78.
10. Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhea, and functional abdominal pain. Aliment Pharmacol Ther. 2007;26(2):237-48.
11. Singh G, Kahler K, Bharathi V, et al. Adults with chronic constipation have significant healthcare resource utilization and costs of care. Am J Gastroenterol. 2004;99:S227.
12. Cash B. Chronic constipation - defining the problem and clinical impact. Medscape Gastroenterol. 2005;7(1). Available by login at: www.medscape.com/viewarticle/501467_1. Accessed May 26, 2008.
13. Bracco A, Kahler K. Burden of chronic constipation must include estimates of work productivity and activity impairment in addition to traditional healthcare utilization. Am J Gastroenterol. 2004;99:S233.
14. Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005;23(5):461-76.
15. Wald A, Scarpignato C, Kamm MA, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 2007;26(2):227-36.
16. Rao SS, Seaton K, Miller MJ, et al. Psychological profiles and quality of life differ between patients with dyssynergia and those with slow transit constipation. J Psychosom Res. 2007;63(4):441-49.
17. Prather CM. Subtypes of constipation: sorting out the confusion. Rev Gastroenterol Disord. 2004;4(suppl 2):S11-S16.
18. Prather CM, Ortiz-Camacho CP. Evaluation and treatment of constipation and fecal impaction in adults. Mayo Clin Proc. 1998;73(9):881-86.
19. Chang JY, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Risk factors for chronic constipation and a possible role of analgesics. Neurogastroenterol Motil. 2007;19(11):905-11.
20. Locke GR 3rd, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ. Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol. 2000;95(1):157-65.
21. Bouvy ML, Buurma H, Egberts TC. Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention. J Clin Pharm Ther. 2002;27(2):107-10.
22. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med. 1996;335(15):1124-32.
23. Singh G, Kahler K, Bharathi V, et al. Constipation in adults: complications and comorbidities. Gastroenterology. 2005;128(suppl 2):A-154.
24. Locke GR 3rd, Pemberton JH, Phillips SF. American Gastroenterological Association medical position statement: guidelines on constipation. Gastroenterology. 2000;119(6):1761-66.
25. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(suppl):S1-S4.
26. Pepin C, Ladabaum U. The yield of lower endoscopy in patients with constipation: survey of a university hospital, a public county hospital, and a Veterans Administration medical center. Gastrointest Endosc. 2002;56(3):325-32.
27. U.S. Preventive Services Task Force. Screening for Colorectal Cancer: Recommendations and Rationale. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); July 2002. AHRQ Web site. Available at: www.ahrq.gov/clinic/3rduspstf/colorectal/colorr.htm. Accessed June 2, 2008.
28. ASGE guideline: guideline on the use of endoscopy in the management of constipation. Gastrointest Endosc. 2005;26(2):199-201.
29. Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolf BG. Simplified assessment of segmental colonic transit. Gastroenterology. 1987;92(1):40-47.
30. Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003; 349(14):1360-68.
31. Fletcher JG, Busse RF, Riederer SJ, et al. Magnetic resonance imaging of anatomic and dynamic defects of the pelvic floor in defecatory disorders. Am J Gastroenterol. 2003;98(2):399-411.
32. Annells M, Koch T. Constipation and the preached trio: diet, fluid intake, exercise. Int J Nurs Stud. 2003;40(8):843-52.
33. Chung BD, Parekh U, Sellin JH. Effect of increased fluid intake on stool output in normal healthy volunteers. J Clin Gastroenterol. 1999;28(1):29-32.
34. Dukas L, Willett WC, Giovannucci EL. Association between physical activity, fiber intake, and other lifestyle variables and constipation in a study of women. Am J Gastroenterol. 2003;98(8):1790-96.
35. Meshkinpour H, Selod S, Movahedi H, Nami N, James N, Wilson A. Effects of regular exercise in management of chronic idiopathic constipation. Dig Dis Sci. 1998;43(11):2379-83.
36. Lembo A. Chronic constipation. AGA Web site. Available at: www.gastro.org/user-assets/Documents/08_Publications/ 06_GIHep_Annual_Review/Articles/Lembo.pdf. Accessed May 5, 2008.
37. Lembo AJ. Clinical crossroads: a 54-year-old woman with constipation-predominant irritable bowel syndrome. JAMA. 2006;295(8):925-33.
38. McEvoy GK, ed. AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists, Inc.
39. Wickersham RM, ed. Drug Facts and Comparisons. St. Louis: Wohers Kluwer Health; 2007.
40. Amitiza [package insert]. Bethesda, MD: Sucampo Pharmaceuticals, Inc; 2008.
41. Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology. 2006;130(3):657-64.
42. Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology. 2005;129(1):86-97.
43. Schiller LR. Review article: the therapy of constipation. Aliment Pharmacol Ther. 2001;15(6):749-63.
44. Voderholzer WA, Schatke W, Mühldorfer BE, Klauser AG, Birkner B, Müller-Lissner SA. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol. 1997;92(1):95-98.
45. McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther. 1998;12(5):491-97.
46. Sondheimer JM, Gervaise EP. Lubricant versus laxative in the treatment of chronic functional constipation of children: a comparative study. J Pediatr Gastroenterol Nutr. 1982;1:223-26.
47. Tolia V, Lin CH, Elitsur Y. A prospective randomized study with mineral oil and oral lavage solution for treatment of faecal impaction in children. Aliment Pharmacol Ther. 1993;5:523-29.
48. Attar A, Lémann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 1999;44(2):226-30.
49. Dipalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102(7):1436-41.
50. U.S. Food and Drug Administration. Letter response to supplemental new drug application. April 29, 2008. Available at: www.fda.gov/cder/foi/ appletter/2008/021908sel-0051tr.pdf. Accessed August 23, 2008.
51. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103(1):170-77.
52. Mahadevan U, Kane S. American Gastroenterology Association Institute. American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy. Gastroenterology. 2006;131(1):278-82.
53. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008, Issue 2. Art. No.: CD006332. DOI: 10.1002/14651858.CD006332.pub2.
54. Department of Health and Human Services. NDA approval letter. NDA 21-964. Available at: www.fda.gov/cder/foi/appletter/2008/ 021964s000ltr.pdf. Accessed August 11, 2008.
55. Alvimopan [package insert]. Exton, PA: Alodor Corporation; 2008.
56. U.S. Food and Drug Administration. FDA announces discontinued marketing of GI drug, Zelnorm, for safety reasons. FDA News. Available at: www.fda.gov/bbs/topics/NEWS/2007/NEW01597.html. Accessed August 11, 2008.
57. Novartis. Zelnorm. Available at: www.zelnorm.com/index.jsp. Accessed August 11, 2008.
58. Lembo AJ. Linaclotide significantly improved bowel habits and relieved abdominal symptoms in adults with chronic constipation: data from a large four-week, randomized, double-blind, placebo-controlled study. Presented at: Digestive Disease Week 2008; May 17-22, 2008; San Diego, CA.
59. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344-54.
60. Volicer L, Lane P, Panke J, Lyman P. Management of constipation in residents with dementia: sorbitol effectiveness and cost. J Am Med Div. Assoc. 2005;6(3 suppl):S32-34.
61. Sturtzel B, Elmadfa I. Intervention with dietary fiber to treat constipation and reduce laxative use in residents of nursing homes. Ann Nutr Metab. 2008;52(suppl 1):54-56.
62. Tufts HealthPlan. Pharmacy medicai necessity guidelines: Amitiza (lubiprostone). May 13, 2008. Available at: www.tuftshealthplan.com/ providers/pdf/pharmacy©iteria/Zelnorm.pdf. Accessed on August 13, 2008.
63. OSF HealthPlans. HMO/POS/QCP medical preauthorization policies and procedures. Available at: www.publicpolicies.osfhealthplans.com/ Preauth.aspx. Accessed August 13, 2008.
64. Yuan CS, Doshan H, Charney MR, et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005;45(5):538-46.
65. Foss JF, O'Connor MF, Yuan CS, Murphy M, Moss J, Roizen MF. Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol. 1997;37(1):25-30.
66. Rao SS, Ozturk R, Laine L. Clinical utility of diagnostic tests for constipation in adults: a systematic review. Am J Gastroenterol. 2005;100(7):1605-15.
67. Berardi RR, Kroon LA, McDermott JH, et al. Handbook of Nonprescription Drugs. 15th ed. Washington, D.C.: APhA Publications; 2006.
68. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppl 2):11,43-47.
69. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997;112(6):2120-37.
70. Robson KM, Kiely DK, Lembo A. Development of constipation in nursing home residents. Dis Colori Rectum. 2000;43(7):940-43.
71. Tariq SH. Constipation in long-term care. J Am Med Dir Assoc. 2007;8(4):209-18.